TL;DR
This study identifies genetic variants that protect against cardiovascular disease (CVD) without increasing the risk of liver disease. By analyzing a large Norwegian cohort, researchers found 76 variants, including 9 that cause a loss-of-function in their respective proteins, that are linked to improved blood lipid profiles. One promising target, ZNF529, when inhibited, led to increased LDL receptor expression and uptake in liver cells, suggesting its potential for treating dyslipidemia and CVD.
What Problem Does This Paper Address?
Cardiovascular disease (CVD) remains a leading cause of death globally, and lowering blood lipids is a key strategy for risk reduction. However, many existing lipid-lowering drugs can increase the risk of adverse effects like fatty liver disease. Furthermore, a significant number of novel drug candidates fail in clinical trials due to a lack of predictive preclinical models and insufficient understanding of long-term consequences. This paper aims to address this by identifying genetic variants that confer a beneficial lipid profile and reduce CVD risk, while crucially avoiding detrimental impacts on liver function, thereby highlighting safer and more effective therapeutic targets.
Methods
The researchers employed a multi-pronged genomic approach to identify potential drug targets. This included:
- Low-coverage whole-genome sequencing (WGS): Used on a subset of participants to identify rare, region-specific variants.
- Targeted genotyping: Expanded on WGS findings, including rare variants.
- Deep genotype imputation: Leveraged a large multi-ethnic reference panel (TOPMed) to impute variants across the genome.
- Genome-wide association studies (GWAS): Conducted on a large cohort to identify associations between variants and blood traits.
- Stepwise conditional analyses: Refined associations to identify independent signals.
- Trans-ancestry meta-analyses: Combined data from Norwegian, Japanese, and Sardinian populations to increase power and fine-map loci.
- Custom array genotyping: Focused on specific variants of interest identified through WGS or clinical relevance.
- In vitro functional characterization: Used human hepatoma cells (HepG2) to investigate the biological mechanisms of promising candidate genes, including siRNA-mediated gene silencing, RNA sequencing, qPCR, and western blotting.
Datasets
The primary dataset used was the HUNT Study from Norway, comprising approximately 69,479 participants for GWAS and up to 57,060 for custom array genotyping. Additional datasets used for trans-ancestry meta-analyses included:
- SardiNIA cohort
- Biobank Japan
For phenome-wide association studies (PheWAS), the UK Biobank (N = 408,961 participants) was utilized.
Key Insights and Ideas
- Genetic support for drug efficacy: The study reinforces the idea that drugs with strong genetic support are more likely to succeed in clinical trials. By identifying genetic variants that naturally confer protection, they are pinpointing genes that are likely to be safe and effective targets.
- Prioritizing safety alongside efficacy: A core innovation is the explicit focus on identifying variants that improve lipid profiles without negatively impacting liver function. This dual criterion is crucial for developing safer CVD therapies.
- Loss-of-function (LoF) variants as key indicators: The identification of LoF variants is particularly valuable. These variants often represent a complete absence of protein function, making their associated phenotypes more definitive and their corresponding genes more attractive drug targets for inhibition.
- ZNF529 as a novel therapeutic target: The detailed functional characterization of ZNF529:p.K405X highlights its role in regulating LDL cholesterol. Its inhibition leading to increased LDL receptor expression and uptake in liver cells is a significant finding, suggesting a novel pathway for lowering LDL-C.
- Cross-trait analysis for comprehensive understanding: Integrating associations with blood traits, disease endpoints (via PheWAS), and in vitro experiments provides a robust framework for prioritizing targets and understanding potential side effects.
Key Results
- 76 presumed causal protein-altering variants identified: These variants are associated with one or more CVD- or liver-related blood traits.
- 11 previously unreported variants: This includes 9 variants predicted to cause loss-of-function (LoF).
- ZNF529:p.K405X variant: Associated with significantly decreased LDL cholesterol (P = 1.3 × 10⁻⁸) without affecting liver enzymes or blood glucose.
- ZNF529 silencing in HepG2 cells: Led to a significant upregulation of the LDL receptor (LDLR) mRNA and protein, and increased DiI-LDL uptake.
- 24 variants associated with disease phenotypes: Out of 64 imputed variants, 24 showed statistically significant associations with one or more disease groups in the UK Biobank PheWAS.
- Two variants with favorable lipid and disease profiles: COBLL1:p.N497D (decreased TG, reduced T2D risk) and LPL:p.S474X (decreased CAD, T2D, hypertension risk) were identified as promising targets.
Limitations and Future Work
- Rodent homolog limitation for ZNF529: The absence of a ZNF529 homolog in rodents limits the use of traditional animal models for further mechanistic studies.
- Low frequency of some variants: The low allele frequency of some promising variants (e.g., ZNF529:p.K405X) made replication in other large cohorts challenging, necessitating the use of specialized genotyping arrays.
- Further mechanistic studies: While ZNF529's role in LDLR regulation is shown, further studies are warranted to fully elucidate the precise mechanisms by which ZNF529 regulates LDLR and LDL uptake in the liver.
- Exploring other identified targets: The study identified numerous other promising variants and genes that warrant further investigation for their therapeutic potential in CVD and metabolic diseases.
- Clinical validation: The ultimate validation of these targets will require preclinical and clinical studies to confirm their safety and efficacy in humans.
Summary updated